eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent.eTheRNA builds on more than 30 years of mRNA manufacturing experience. Since 2018, all RNA production is performed in the brand new GMP authorized facility in Niel, Belgium.We now offer our expertise and capability to other parties interested in having their RNA manufactured according to their needs. We produce both non-GMP or research grade material and GMP grade material to be used in clinical trials

Arctoris is a global platform company that is transforming drug discovery. Combining its powerful robotic platform, Ulysses, with an experienced team, Arctoris runs integrated drug discovery projects with its partners worldwide, rapidly delivering reliable, reproducible, and fully auditable datasets enabling better decision-making early in the drug discovery process. Arctoris thereby enables leaders in biotech and pharma to take their programs from idea to IND and into the clinic faster.Over the past five years, Arctoris has grown from a technology startup to a globally operating company with partners on four continents, operations in Oxford, Boston and Singapore, and a team of seasoned drug hunters and experienced engineers.

Specialising in bioinformatics, structural biology and chemogenomics disciplines, we license world class software on behalf of renowned academic research groups and also offer contract research and consultancy services.

At Glamorous AI our focus is the application of AI/ML to small, sparse and noisy data sets, with the objective of bringing drugs to every target. Our premise is that 80% of drug targets are intractable using current methods, simply based on the lack of available data. Our unique platform ROSALIND AI is:• The first end-to-end AI platform for drug discovery• The largest repository of state-of-the-art AI models• Trained on one of largest data repositories (10x larger than public sources)• Able to integrate pre-trained and bespoke models in R&D workflows• 2x less data required to train our predictive models• Up to 8% more accurate in prediction of chemical properties over current AI/ML methods• Pre-trained on secure cloud platform for use with your own data cataloguesWe have applied ROSALIND AI to the following challenging applications:• Design of a novel inhibitors for KEAP1 purely by AI in only 6 weeks• Reinforcement learning to steer generation of NCEs to drug-like and BBB permeable compounds• Accurate predictions of ADMET properties using 50% less data – valuable when data is expensive/difficult to generate• Increasing the diversity of, and maximising value from, large chemical libraries

Supported Wobble Genomics from inception through its Innovate UK funding journey, securing follow on funding and preparing for spin-out and investor readiness.

MIP Diagnostics Ltd was founded in 2015 as a spin out from the University of Leicester by several leading experts in the field, including Prof. Sergey Piletsky, in order to commercialise various forms of Molecularly Imprinted Polymers (MIPs), sometimes called "plastic antibodies". Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. Whilst MIPs are exceptionally robust polymers [plastics], nanoMIPS are sufficiently small to be essentially soluble. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. They can withstand harsh chemical environments, such as extremes of pH, seawater or high concentrations of organic solvents. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using the proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP within just two weeks of receiving the target.No immune response is required and no animals are used in the manufacture of MIPs.http://www.mip-dx.com/

Chemogenomix provides knowledge-based approaches to computational biology, bioinformatics, structural biology and chemogenomics.We license world class software on behalf of several renowned academic research groups and also offer contract research and consultancy services. Our experience is deep and we work with clients to tackle a variety of research challenges.If this approach strikes a chord, please contact me.

I am an independent biotechnology/pharmaceutical consultant with 25+ years experience in the life science, pharmaceutical and biotech industries. My experience is international - I have lived and worked in the USA and Europe, and have extensive experience and connections in Japan with over 50 visits. Below a summary of my recent roles:• Business development and marketing support for company promoting bioinformatics knowledge base.• Interim CEO role for stem cell University spin-out, to assess market opportunity, develop full business plan and financial plan, market plan to VC and Angel investor groups.• CEO for VC funded nanomaterial start-up to review business opportunity. Assessed technology strengths and market opportunity, developed new business and financial plan and finalised further investment. R&D team realigned, commercial strategy and international business development team developed.• Interim Business Development Director role for ADMET service provider, to develop and implement plan for entering Japanese market.• Consultancy project sponsored by Regional Development Agency for identification and assessment of potential new biotechnology start-ups from local University groups.• Consultancy brief from Regional Development Agency to identify new opportunities and potential tenants for purpose built R&D facility.• Development of new website, including design and all textual and graphical content for biotechnology company.

FibromEd is an exciting new company focused on providing novel solutions for assessing liver-based drug toxicity and metabolism in pharmaceutical research.In particular we develop novel assays using hepatocytes derived from human stem cells to predict human liver-based drug failure.

Label free screening using gold nanoparticles and localised surface plasmon resonance (lspr). We employ a broadly enabling technology that enables high throughput, robust and sensitive label free screens for both small molecule and antibody discovery & characterisation. No dedicated instrumentation is required.